Clinical Trial Update: Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 dose-range finding study of the rBet v1-FV vaccine in adults with birch pollen–induced seasonal allergic rhino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis
• Birch Pollen-induced Allergic Rhinoconjunctivitis

Drugs mentioned

• rBet v1-FV (recombinant Bet v 1-FV allergen immunotherapy)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Allergic Rhinoconjunctivitis | Phase 2 | Status: COMPLETED